LipiFlow thermal Pulsation System
Recall Z-0093-2017, part of FDA recall event 75163. See Tearscience's company page.
Tearscience, Inc started this Class II device recall on Sep 13, 2016 (voluntary: firm initiated); FDA lists it as terminated, terminated Feb 9, 2017.
- Classification: Class II
- Started: Sep 13, 2016
- Status: Terminated
Complaints related to an error condition occurring during patient treatment where the FipiFlow System automatically stopped treatment after detecting a problem with the Activator.
- Product
- LipiFlow thermal Pulsation System, consisting of Console and Activator, Model LFD-1100 The LipiFlow Thermal Pulsation System is intended for use by physicians as a prescription device for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye.
- Quantity
- 1,200 Activators (120 boxes of 10 units)
- Lots and codes
- Lot 201615220020
- Distribution
- US Distribution including states of: AK, AR, CA, CO, FL, GA, ID, IL, IN, LA, MD, MA, MN, MO, NV, NM, NY, NC, OH, OK, OR, PA, SC, TN, TX, VA , WA, WI and Puerto Rico.
- Recalling firm
- Tearscience, Inc, Morrisville, NC, United States
- How the firm notified
- Letter
- FDA classified
- Oct 17, 2016
Newest first, one product per recall event; search them all
- LipiFlow Thermal Pulsation System/LipiFlow, System Activator (Disposable), Rx Only, SterileZ-1535-2017 · Class II · Jan 30, 2017 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA device enforcement reports